180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease
Yahoo! Finance
PALO ALTO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced, following publication of promising data from a Phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, that 180 Life Sciences has initiated preliminary consultations with regulat
Continue Reading